View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • Herman Caspersen
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Stian Wibstad
 PRESS RELEASE

EcoVadis Gold rating validates Ontex’s business sustainability commitm...

EcoVadis Gold rating validates Ontex’s business sustainability commitments and performance for second year in a row Aalst, Belgium, February 19, 2026 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care solutions, announces that it has been awarded a Gold rating by EcoVadis for the second consecutive year. EcoVadis, a global leader in business sustainability assessments, awarded Ontex a higher total score year on year, placing the company in the top 3% of companies assessed globally. The recognition reflects the solid foundations Ontex has bu...

 PRESS RELEASE

EcoVadis goud-beoordeling bevestigt voor tweede jaar op rij duurzaamhe...

EcoVadis goud-beoordeling bevestigt voor tweede jaar op rij duurzaamheidsengagement en -prestaties van Ontex Aalst, België, 19 februari 2026 – Ontex Group NV [EURONEXT: ONTEX], een toonaangevende ontwikkelaar en producent van persoonlijke verzorgingsproducten, heeft het tweede jaar op rij een gouden medaille van EcoVadis ontvangen. EcoVadis, wereldwijd toonaangevend in duurzaamheidsbeoordelingen van bedrijven, kende Ontex een hogere totaalscore toe dan vorig jaar. Ontex behoort daarmee vandaag tot de top 3% van de wereldwijd beoordeelde bedrijven. De erkenning weerspiegelt de solide funda...

Carole Braudeau
  • Carole Braudeau

Credit Morning 02/18/2026

Tereos : -57% EBITDA over 9M 25/26. Guidance reaffirmed for a leverage peak at 6x as of March 31|Celanese – still challenging conditions but margins and FCF generation remain healthy|Emeis reported 2025 results ahead of expectations|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 18/02/2026

Tereos : -57% d’EBITDA sur les 9M 25/26. Prévision réitérée d’un pic de levier à 6x au 31 mars|Celanese – still challenging conditions but margins and FCF generation remain healthy|Emeis a publié des résultats 2025 supérieurs aux attentes|

ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • Herman Caspersen
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Stian Wibstad
Florent Laroche-Joubert
  • Florent Laroche-Joubert
Florent Laroche-Joubert
  • Florent Laroche-Joubert
ABGSC Energy Research ... (+7)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • Herman Caspersen
  • John Olaisen
  • Lars Trongaard Brattli
  • Martin Mauseth
  • Stian Wibstad
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Tanvi Arora
  • Tanvi Arora

Ontex - Earnings Flash - FY 2025 Results - Lucror Analytics

Ontex has released weak FY 2025 results. The company downgraded its guidance twice in the year, due to soft demand amid weak consumer sentiment, high promotional activity from A brands and supply-chain constraints, as well as increases in raw-material costs. Meanwhile, H2 was more challenging than management's initial expectations. Looking ahead, Ontex anticipates that market conditions will remain soft. That said, management is optimistic that performance will improve gradually through the year...

Felix Fischer ... (+7)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
  • Trung Nguyen

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Verisure, TGS ASA, Ontex, Odido, Bombardier, Allwyn (formerly Sazka), Mehilainen, Softbank Group, Ineos, Iceland Foods, Ineos Quattro

 PRESS RELEASE

GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the U...

GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales   Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout ...

 PRESS RELEASE

GENFIT va recevoir un paiement d’étape de 20 M$ suite au dépassement d...

GENFIT va recevoir un paiement d’étape de 20 M$ suite au dépassement du seuil des 200 M$ de ventes nettes d’Iqirvo® par Ipsen dès sa première année complète de commercialisation Ventes nettes d’Iqirvo® dans la PBC par Ipsen atteignant 88 M$ au 4T25, portant le total annuel pour 2025 à 208 M$, déclenchant le premier paiement d’étape1 commercial pour GENFIT plus tôt que prévu Confirmation par Ipsen du lancement d’une Phase 3 dans la PSC, ouvrant une nouvelle opportunité de création de valeur potentielle pour GENFITL’étude de Phase 1b de GENFIT dans le CCA progresse comme prévu : Nouvelle coho...

Carole Braudeau
  • Carole Braudeau

Credit Morning 02/12/2026

URW continues its strong momentum at the end of the year|Verisure ends fiscal year 2025 on a high note|Greek banks – A Supreme Court ruling could impact banks and NPL management|

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch